Fluidigm Announces Conference Call and Webcast of Fourth Quarter and Full Year 2020 Financial Results
January 07 2021 - 4:02PM
Fluidigm Corporation (Nasdaq:FLDM), an innovative
biotechnology tools provider with a vision to improve life through
comprehensive health insight, today announced that it will
report fourth quarter and full year 2020 financial results on
Wednesday, February 10, 2021, after the close of the market.
Chris Linthwaite, President and CEO, and Vikram Jog, Chief
Financial Officer, will host a conference call and webcast at 2:00
p.m. PT, 5:00 p.m. ET, on February 10, 2021, to discuss fourth
quarter and full year 2020 financial results and operational
progress. A press release outlining the financial results will be
publicly distributed before the call.
Individuals interested in listening to the conference call may
do so by dialing:
US domestic callers: (877) 556-5248Outside US
callers: (720) 545-0029Please reference Conference ID: 4664638
A live webcast of the conference call will be available online
from the Investor Relations page of the Company’s website at Events
& Presentations. The link will not be active until 1:45 p.m.
PT, 4:45 p.m. ET, on February 10, 2021.
After the live webcast, the call will be archived on Fluidigm’s
Investor Relations page at investors.fluidigm.com. In addition, a
telephone replay of the teleconference will be available
approximately 90 minutes after the end of the call.
The replay dial-in numbers are:
US domestic callers: (855) 859-2056Outside US:
(404) 537-3406Please reference Conference ID: 4664638
The telephone replay will be available until February 17.
About FluidigmFluidigm (Nasdaq:FLDM)
focuses on the most pressing needs in translational and clinical
research, including cancer, immunology, and immunotherapy. Using
proprietary CyTOF® and microfluidics technologies, we develop,
manufacture, and market multi-omic solutions to drive meaningful
insights in health and disease, identify biomarkers to inform
decisions, and accelerate the development of more effective
therapies. Our customers are leading academic, government,
pharmaceutical, biotechnology, plant and animal research, and
clinical laboratories worldwide. Together with them, we strive to
increase the quality of life for all. For more information,
visit fluidigm.com.
Fluidigm, the Fluidigm logo, Advanta, and CyTOF are
trademarks and/or registered trademarks of Fluidigm
Corporation in the United States and/or other
countries. The Advanta™ Dx SARS-CoV-2 RT-PCR Assay is for In Vitro
Diagnostic Use. It is for Use under Emergency Use Authorization
Only. Rx Only. Other Fluidigm products are provided for Research
Use Only. Not for use in diagnostic procedures.
Available InformationWe use our website
(fluidigm.com), investor site (investors.fluidigm.com), corporate
Twitter account (@fluidigm), Facebook page (facebook.com/Fluidigm),
and LinkedIn page (linkedin.com/company/fluidigm-corporation) as
channels of distribution of information about our products, our
planned financial and other announcements, our attendance at
upcoming investor and industry conferences, and other matters. Such
information may be deemed material information, and we may use
these channels to comply with our disclosure obligations under
Regulation FD. Therefore, investors should monitor our website and
our social media accounts in addition to following our press
releases, SEC filings, public conference calls, and
webcasts.
Contact:
Agnes LeeVice President, Investor Relations650 416
7423agnes.lee@fluidigm.com
Fluidigm (NASDAQ:FLDM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Fluidigm (NASDAQ:FLDM)
Historical Stock Chart
From Sep 2023 to Sep 2024